Fig. 4
From: TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
Intra-tumoral MGN1703 combined with systemic 9D9-IgG2a anti-CTLA-4 antibody cures poorly immunogenic B16-F10 melanoma. C57BL/6 J mice were injected with 2.5 × 104 B16-F10 melanoma cells on the right and left flanks. The right flank tumor was then injected with 30μg of the TLR9 agonist MGN1703 or PBS in 50ul on days 3, 6 and 9 with or without concordant injection of 100μg of the CTLA-4 blocking antibody 9D9-mIgG2a i.p. Survival was monitored and mice were euthanized when tumors reached 1000mm3 (n = 2 independent experiments of 5–10 mice / group, all shown). Statistical significance was calculated using the log-rank (Mantel-Cox) test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001